 |
|
|
|
 |
|
|
| Article 1 to 10 out of 12 concerning Eden Biodesign Ltd.
|
-
Eden Biodesign expands Research Triangle Park Facility
(06/19/2008)
Eden Biodesign Ltd. confirmed its expansion plans for Eden Biodesign, Inc., the Group's US subsidiary, with the announcement of a facility in the Research Triangle Park, North Carolina. Eden Biodesign, Inc., will offer a range of cell line/strain ...
-
Eden Biodesign advances toward establishing its U.S. operation
(06/10/2008)
Michael Faughnan appointed as Business Development Director
Eden Biodesign announced the appointment of Michael Faughnan as Business Development Director of its US subsidiary, Eden Biodesign, Inc. Michael will be supporting Dr. Roger Lias, President of Eden Biodesign, Inc. and Group Commercial Director, with ...
-
Eden Biodesign and Stealthyx Therapeutics sign deal to develop enhanced treatment for rheumatoid arthritis
(03/10/2008)
Eden Biodesign Ltd and Stealthyx Therapeutics Ltd, a London based biotechnology company, announced that they have entered into an agreement to develop and produce Stealthyx's lead therapeutic candidate that the company is evaluating for treatment of ...
-
Eden Biodesign and iQur sign deal to develop a combined vaccine for the treatment of hepatitis A and B
(02/05/2008)
Eden Biodesign Ltd and iQur Ltd, a speciality pharma company at the forefront of research to combat liver disease, announced that they have entered into an agreement to develop iQur's 'tandem core' vaccine for hepatitis A and B.Eden Biodesign will ...
-
ImmunoBiology extends its collaboration with Eden Biodesign to develop a new generation vaccine for influenza
(11/14/2007)
Eden Biodesign Ltd and ImmunoBiology Ltd (ImmBio) have elected to extend their initial collaboration to develop ImmBio's innovative influenza vaccine. The new contract covers a range of development and cGMP manufacturing services to produce material ...
-
Eden Biodesign appoints Roger Lias as president Eden Biodesign, USA
(11/07/2007)
Eden Biodesign Ltd announced the appointment of Dr Roger Lias as President Eden Biodesign, USA. Roger has extensive experience in the biotechnology industry with a specific emphasis on biomanufacturing services. Roger's responsibilities will include ...
-
Eden Biodesign and Borean Pharma ApS sign deal to develop novel therapeutic candidate for the treatment of cancer
(09/12/2007)
Eden Biodesign Ltd and Borean Pharma ApS announced that they have signed an agreement under which Eden will manufacture MBP-DC-SIGN, a novel therapeutic candidate for the treatment of a range of cancers, for Borean to use in key preclinical studies. ...
-
Eden Biodesign selected by Cancer Research UK to develop and manufacture two therapeutic candidates
(09/06/2007)
Treatment of advanced intra-abdominal and head and neck cancer
Eden Biodesign Ltd announced that it has signed agreements with Cancer Research UK (CR-UK) to provide consultancy, process development and manufacturing services for two of CR-UK's leading gene therapy products: Ad-hTR-NTR for advanced ...
-
Eden Biodesign and the University of Manchester Intellectual Property Limited develop cancer treatment
(08/08/2007)
Eden Biodesign Ltd, announced that it has been selected by the University of Manchester Intellectual Property Limited (UMIP) to provide a range of services for the development of a novel therapeutic for treatment of macular degeneration and ...
-
Eden Biodesign and the University of Birmingham develop therapeutic candidate for the treatment of autoimmune diseases
(08/02/2007)
Eden Biodesign Ltd announced today that it has been selected by the University of Birmingham to develop and produce vOX2:Fc, a novel therapeutic candidate for the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. ...
Additional information
Eden Biodesign Ltd.
Liverpool, United Kingdom
Company
|
|
|
|
|
|
Top
